Media Release  |  April 22, 2026 New Research Highlights Muno-IgY®’s Potential to Support Gut Microbiome Balance Calgary, Alberta, Canada – April 22, 2026 – IGY Life Sciences (“IGY Life Sciences”) - New published research in Microbiome Research Reports adds to the emerging evidence base for Muno-IgY®, with findings [...]

Press Release  |  February 18, 2026 New Clinical Trial Published in Nutrients Examines Muno IgY® and Immune Related Outcomes Calgary, Alberta, Canada – February 18, 2026 – IGY Immune Technologies & Life Sciences Inc. (“IGY Life Sciences”) is pleased to announce the publication of its latest clinical [...]

Press Release  |  May 23, 2024 Thunder Bay, Ontario, Canada – May 23, 2024 – IGY Immune Technologies & Life Sciences Inc. (“IGY Life Sciences”) is delighted to announce that it has achieved Self-Affirmed GRAS status for Muno-IgYTM, the broad spectrum IgY for dietary supplement applications produced in Alberta, [...]

Press Release  |  March 24, 2023 Thunder Bay, Ontario, Canada - July 25, 2022 – IGY Life Sciences and Immune Technologies Inc.(the "Company" or "IGY Life Sciences") is pleased to announce the closing of $12.8 million (CDN) in financing this week. This represents the largest single injection of funds into the Company since it [...]

Businesswire  |  June 8, 2020 THUNDER BAY, Ontario--(BUSINESS WIRE)--IGY Life Sciences today announced it will be collaborating with clinical data and regulatory experts, MMS Holdings (MMS), to further the development of IgY-110, an anti-CoV-2 therapeutic antibody with a focus on a nasal spray application. This novel approach of an IgY antibody in a [...]